Abstract 1888P
Background
The increasing presence of cancer patients in palliative care within emergency departments (ED) worldwide calls for improved care quality. These patients often undergo unnecessary invasive procedures due to challenges in promptly assessing their treatment needs. We developed PalliScore, a rapid assessment tool aimed at helping medical professionals quickly identify palliative care patients in the ED who are less likely to benefit from invasive procedures or ICU admission.
Methods
We retrospectively analyzed data from cancer patients in palliative care admitted to the ED of our hospital in Southeast Brazil, calculating their PalliScore upon admission. This four-step tool incorporates diagnosis of an incurable and life-threatening disease, special care situations (e.g., family or medical team disagreements, uncontrolled symptoms), the “surprise question” (Would you be surprised if this patient died within the next 12 months?), and performance status (ECOG or PPS). Each criterion is scored to reflect the PalliScore, with a threshold of ≥5 suggesting a need to consider limiting invasive interventions after thorough discussion with the patient and healthcare providers.
Results
From March 2021 to July 2023, we assessed 521 patients; 70 (13.68%) received limited intervention care while 449 received intensive care. The average PalliScore was 6.50 for the limited care group and 2.77 for the intensive care group. Statistical analysis using an unpaired t-test showed a significant difference in PalliScore between the groups (odds ratio 3.73, p < 0.0001). Notably, 16.7% of patients with a PalliScore ≥ 5 still received intensive care treatments, whereas 10% of patients with a PalliScore < 5 received limited intervention care.
Conclusions
PalliScore effectively aids ED physicians in making informed decisions regarding invasive procedures and ICU admissions, thereby potentially improving the quality of care for cancer patients in palliative settings. This tool highlights the complex nature of decision-making in palliative care, emphasizing the need for sensitive and individualized patient assessments.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1852P - The use of patient-reported outcome measures to assess toxicities and quality of life associated with immune checkpoint inhibitor therapy: A systematic review
Presenter: Poorni Jaganathan
Session: Poster session 12
1853P - Risk model for overall survival (OS) based on composite patient-reported outcomes (PROs) in aNSCLC patients treated with first-line (1L) cemiplimab-based therapy
Presenter: David Gandara
Session: Poster session 12
1854P - Assessing mortality rates within 30 days following the last dose of immunotherapy: A multi-center retrospective study
Presenter: Kadriye Baskurt
Session: Poster session 12
1855P - Analyzing the utility of the cancer therapy satisfaction questionnaire (CTSQ)
Presenter: Carolina Navas
Session: Poster session 12
1856P - Prediction of clinically significant bleeding in anticoagulated patients for cancer-associated venous thromboembolism: Validation of B-CAT score in a cohort from the TESEO study
Presenter: Javier López Robles
Session: Poster session 12
1857P - Machine learning models (MLM) predict venous thromboembolism events (VTE) in Asian oncological inpatients better than the Khorana Score (KS)
Presenter: Jerold Loh
Session: Poster session 12
1858P - Efficacy and safety of thromboprophylaxis in oncology patients with Khorana score<2: Combined results from GMaT and ACT4CAT studies
Presenter: Nikolaos Tsoukalas
Session: Poster session 12
1860P - The impact of sodium-glucose cotransporter-2 inhibitors on thrombosis and cardiovascular disease in patients with polycythemia vera or essential thrombocytopenia
Presenter: Yuanping Hsia
Session: Poster session 12
1861P - Poly (ADP-Ribose) polymerase inhibitors (PARPI): Associated thrombosis in patients with ovarian cancer
Presenter: Manuel Sanchez Canovas
Session: Poster session 12
1862P - A single-arm, phase II trial of hetrombopag for the treatment of concurrent chemoradiotherapy-induced thrombocytopenia in patients with advanced solid tumors
Presenter: Weiwen Zhou
Session: Poster session 12